Sermonix Pharma Using Guardant Health CDx to Screen Breast Cancer Patients for Lasofoxifene Trial
The ELAINE-3 study, a Phase III trial, will use the Guardant360 CDx liquid biopsy test to screen patients for ESR1 mutations.
Coding Variants in Five Breast Cancer Risk Genes Linked to Contralateral Breast Cancer
Researchers characterized contralateral breast cancer risk and breast cancer survival patterns associated with coding germline variants in known breast cancer-related genes.
Breast Cancer Genomic Recurrence Signature Influenced by BMI in Young Patients
In younger Korean women with estrogen receptor-positive, HER2/ERBB2-negative breast cancer, higher body mass index appeared to coincide with a higher Oncotype Dx recurrence score.
Mutations in FOXA1 Gene Can Affect Breast Cancer Patients' Response to Therapy
A new study found that FOXA1 missense mutations were enriched in metastatic breast tumors and
At the American Society of Clinical Oncology's virtual meeting, investigators presented two new studies of BluePrint classification patterns.